Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data FILANA THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
9.18
7.62
2.97
24.8
68
89.4
69.6
26.6
General and administrative
5.78
4.33
3.69
3.39
3.74
8.06
12
16.5
71.8
68.8
Operating expenses
15
11.9
6.66
4.96
6.45
32.9
80
106
141
95.4
Operating income
-15
-11.9
-6.66
-4.96
-6.45
-32.9
-80
-106
-141
-95.4
Other non-operating income
0.43
1
0.91
0.41
-0.2
Income tax
0
0
Net income
-14.9
-11.9
-6.56
-4.63
-6.33
-32.4
-76.2
-97.2
-24.3
-91
EBITDA
-14.9
-11.9
-6.59
-4.9
-6.42
-32.6
-79.2
-105
-140
-94.5
EPS, basic
-2.28
-1.82
-0.61
-0.27
-0.24
-0.82
-1.90
-2.32
-0.53
-1.88
EPS, diluted
-2.28
-1.82
-0.61
-0.27
-0.24
-0.82
-1.90
-2.32
-1.46
-1.88
Shares, basic (weighted)
6.52
6.54
10.7
17.4
26.1
39.4
40.2
41.9
46.3
48.3
Shares, diluted (weighted)
6.52
6.54
10.7
17.4
26.1
39.4
40.2
41.9
46.6
48.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
16.6
10.5
19.8
23.1
93.5
233
201
121
129
95.5
Short-term investments
2.1
Other current assets
0.36
0.18
0.23
0.27
0.49
11
0.16
0.29
0.04
0.06
Total current assets
19.1
10.7
20
23.3
94
244
211
130
137
97.7
Property, plant and equipment
0.23
0.16
0.09
0.05
0.01
20.6
22.9
21.9
21
20.6
Lease right-of-use assets
0.09
0.3
0.21
0.12
0
Intangible assets
1.08
1.08
0.62
0.18
0.04
0.19
Other non-current assets
0.01
0.01
0.4
Total assets
19.3
10.8
20.1
23.5
94.3
267
235
152
158
118
Accounts payable
0.3
0.42
0.29
0.45
0.91
7.13
4.02
Accrued liabilities
0.03
0.4
0.16
0.78
0.72
2.8
2.28
0.2
1.36
1.63
Total current liabilities
0.67
1.13
0.51
1.39
1.87
12.5
7.06
14.2
11.8
43.8
Lease liabilities
0.24
0.14
0.04
0
Other non-current liabilities
0.19
0.2
0
0.08
0.12
Total liabilities
0.67
1.13
0.51
1.39
2.1
12.9
7.3
14.2
11.8
44
Paid-in capital
164
167
184
191
267
461
511
518
551
570
Retained earnings
-145
-157
-164
-169
-175
-207
-284
-381
-405
-496
Shareholders' equity
18.6
9.7
19.6
22.1
92.2
254
228
137
146
74.4
Total equity
18.6
9.7
19.6
22.1
92.2
254
228
137
146
74.4
Total liabilities and equity
19.3
10.8
20.1
23.5
94.3
267
235
152
158
118
Shares outstanding
6.59
6.6
17.2
21.8
35.2
40
41.7
42.2
48.2
48.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.9
-11.9
-6.56
-4.63
-6.33
-32.4
-76.2
-97.2
-24.3
-91
Depreciation and amortization
0.06
0.07
0.07
0.06
0.02
0.31
0.8
1.08
0.95
0.9
Stock-based compensation
4.33
2.97
2.39
1.3
0.99
1.76
2.07
4.59
16.3
19.6
Change in payables
-0.71
0.13
-0.13
0.16
0.46
6.22
-3.45
6.9
-2.92
34
Cash from operations
-12.2
-8.24
-4.77
-2.51
-5.38
-30.2
-77.5
-82
-117
-32.3
Capital expenditures
-0.08
-0.02
-22.2
-2.71
-0.41
-0.1
-0.58
Purchases of investments
-4.14
-0.4
Sales and maturities of investments
2.05
2.1
Cash from investing
-2.17
2.1
-0.02
0.36
-22.2
-2.71
-0.41
-0.1
-0.58
Stock issued
14.1
70.3
190
47.3
0
0
0.09
Cash from financing
-0.28
14.1
5.81
75.4
192
47.8
2.56
124
-0.24
Net change in cash
-14.7
-6.14
9.33
3.27
70.4
140
-32.4
-79.9
7.44
-33.1
Free cash flow
-12.3
-2.53
-52.4
-80.2
-82.4
-117
-32.8
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $0.75 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-114.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-71.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-48.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-31.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-4.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-24.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-20.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
4.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
6.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
13.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.19x
Current assets / current liabilities.
Quick ratio
2.16x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.16x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/B
0.53x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.53x
Market cap / tangible book value, when positive.
Earnings yield
-215.6%
Net income / market cap (the inverse of P/E).
Was FILANA THERAPEUTICS, INC. profitable in fiscal 2025?
No. It reported a net loss of $91.0M.
How much free cash flow did FILANA THERAPEUTICS, INC. generate in fiscal 2025?
Cash from operations of $32.3M minus capital expenditures of $581.0K left free cash flow of -$32.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.